'Ctx efficacy' presentation slideshows

Cotrimoxazole Prophylaxis in HIV positive individuals Group A

Cotrimoxazole Prophylaxis in HIV positive individuals Group A. Conclusions 1. Strong but still accumulating evidence that CTX is beneficial in WHO stage 2, 3 or 4 or if CD4 <200. reduction of morbidity and mortality (mortality: except for stage 2) slows HIV disease progression (Uganda)

183 views • 8 slides